» Articles » PMID: 20354767

Nanoparticles for Local Drug Delivery to the Oral Mucosa: Proof of Principle Studies

Overview
Journal Pharm Res
Specialties Pharmacology
Pharmacy
Date 2010 Apr 1
PMID 20354767
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To determine if solid lipid nanoparticles represent a viable strategy for local delivery of poorly water soluble and unstable chemopreventive compounds to human oral tissues.

Methods: Nanoparticle uptake and compound retention evaluations employed monolayer-cultured human oral squamous cell carcinoma (OSCC) cell lines and normal human oral mucosal explants. Feasibility of nanoparticle delivery was also evaluated with respect to the presence of phase-III efflux transporters in normal oral mucosal tissue and OSCC tissues.

Results: Functional uptake assays confirmed significantly greater internalization of nanoparticle-delivered fluorescent probe relative to free-fluorescent probe delivery, while concurrently demonstrating nanoparticle uptake rate differences among the OSCC cell lines and the phagocytic control human monocyte cell line. Mucosal explants exhibited nanoparticle penetration and internalization in the spinous and basal epithelial layers (7/10 specimens), and also exhibited the presence of the phase-III efflux transporters multidrug resistance-associated protein 1 (MRP1) and breast cancer resistance protein (BCRP).

Conclusions: These data confirm nanoparticle internalization by OSCC cells and support the premise that nanoparticle-based delivery provides higher final intracellular levels relative to bolus administration. Furthermore, the penetration and subsequent internalization of nanoparticles within the proliferating basal layer cells demonstrates the feasibility of nanoparticle formulations for local delivery and stabilization of oral chemopreventive compounds.

Citing Articles

Localized Drug Delivery in Different Gastrointestinal Cancers: Navigating Challenges and Advancing Nanotechnological Solutions.

Hasan A, Cavalu S, Kira A, Hamad R, Abdel-Reheim M, Elmorsy E Int J Nanomedicine. 2025; 20():741-770.

PMID: 39845772 PMC: 11752831. DOI: 10.2147/IJN.S502833.


Perspectives on the Application of Nanomaterials in Medical and Dental Practices.

Rathi S, Reche A, Dhamdhere N, Bolenwar A Cureus. 2023; 15(8):e43565.

PMID: 37719580 PMC: 10503254. DOI: 10.7759/cureus.43565.


Mucopenetrating Janus Nanoparticles For Field-Coverage Oral Cancer Chemoprevention.

Habibi N, Bissonnette C, Pei P, Wang D, Chang A, Raymond J Pharm Res. 2023; 40(3):749-764.

PMID: 36635487 PMC: 10036282. DOI: 10.1007/s11095-022-03465-x.


Novel Strategies for the Bioavailability Augmentation and Efficacy Improvement of Natural Products in Oral Cancer.

Sachdeva A, Dhawan D, Jain G, Yerer M, Collignon T, Tewari D Cancers (Basel). 2023; 15(1).

PMID: 36612264 PMC: 9818473. DOI: 10.3390/cancers15010268.


Patches as Polymeric Systems for Improved Delivery of Topical Corticosteroids: Advances and Future Perspectives.

Dubashynskaya N, Skorik Y Int J Mol Sci. 2022; 23(21).

PMID: 36361769 PMC: 9657685. DOI: 10.3390/ijms232112980.


References
1.
Cui Z, Mumper R . Bilayer films for mucosal (genetic) immunization via the buccal route in rabbits. Pharm Res. 2002; 19(7):947-53. DOI: 10.1023/a:1016454003450. View

2.
Clifford J, Menter D, Wang M, Lotan R, Lippman S . Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res. 1999; 59(1):14-8. View

3.
Rodrigo K, Rawal Y, Renner R, Schwartz S, Tian Q, Larsen P . Suppression of the tumorigenic phenotype in human oral squamous cell carcinoma cells by an ethanol extract derived from freeze-dried black raspberries. Nutr Cancer. 2006; 54(1):58-68. PMC: 2392889. DOI: 10.1207/s15327914nc5401_7. View

4.
Madhav N, Shakya A, Shakya P, Singh K . Orotransmucosal drug delivery systems: a review. J Control Release. 2009; 140(1):2-11. DOI: 10.1016/j.jconrel.2009.07.016. View

5.
Lippman S, Lee J, Martin J, El-Naggar A, Xu X, Shin D . Fenretinide activity in retinoid-resistant oral leukoplakia. Clin Cancer Res. 2006; 12(10):3109-14. DOI: 10.1158/1078-0432.CCR-05-2636. View